Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[41] HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pugach, Pavel
Marozsan, Andre J.
Ketas, Thomas J.
Landes, Elissa L.
Moore, John P.
Kuhmann, Shawn E.
VIROLOGY, 2007, 361 (01) : 212 - 228
[42] HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization
Vila-Coro, AJ
Mellado, M
de Ana, AM
Lucas, P
del Real, G
Martinez, C
Rodriguez-Frade, JM
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3388 - 3393
[43] Effects of CCR2 and CCR5 polymorphisms on HIV-1 infection in Thai females
Wichukchinda, Nuanjun
Nakayama, Emi E.
Rojanawiwat, Archawin
Pathipvanich, Panita
Auwanit, Rattana
Vongsheree, Suthon
Ariyoshi, Koya
Sawanpanyalert, Pathom
Shioda, Tatsuo
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (03) : 293 - 297
[44] CCR5 promoter polymorphisms and HIV-1 perinatal transmission in Brazilian children
de Souza, PR
Arraes, LC
de Lima, JL
Bruneska, D
Milanese, M
Crovella, S
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2006, 69 (01) : 77 - 84
[45] Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection
Caldwell, David J.
Evans, Jeffery D.
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) : 3231 - 3242
[46] The HIV-1 co-receptor CCR5 binds to α-catenin, a component of the cellular cytoskeleton
Schweneker, M
Bachmann, AS
Moelling, K
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 325 (03) : 751 - 757
[47] Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians
Kaur, Gurvinder
Singh, P.
Rapthap, C. C.
Kumar, N.
Vajpayee, M.
Sharma, S. K.
Wanchu, A.
Mehra, N. K.
HUMAN IMMUNOLOGY, 2007, 68 (05) : 454 - 461
[48] The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through Gαi-protein signalling
Lin, Yea-Lih
Mettling, Clement
Portales, Pierre
Reant, Brigitte
Robert-Hebmann, Veronique
Reynes, Jacques
Clot, Jacques
Corbeau, Pierre
AIDS, 2006, 20 (10) : 1369 - 1377
[49] Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1
Tallant, Matthew D.
Duan, Maosheng
Freeman, George A.
Ferris, Robert G.
Edelstein, Mark P.
Kazmierski, Wieslaw M.
Wheelan, Pat J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1394 - 1398
[50] Global stability of a HIV-1 CCR5 gene therapy with suicide gene
Liu, Junmei
Ma, Yonggang
SYSTEMS SCIENCE & CONTROL ENGINEERING, 2024, 12 (01)

← 1 2 3 4 5 →